Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPIC: Pembrolizumab and Doxorubicin in Advanced Endometrial Cancer
NCT03276013Phase 2Completed
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- May 2018
- Primary completion
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in endometrial cancer (EC), sponsored by Vall d'Hebron Institute of Oncology. Started May 2018; status: completed.
02
Drugs
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03276013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03276013.